The next-generation in vitro diagnostics (ivd) market size has grown rapidly in recent years. It will grow from $117.97 billion in 2025 to $129.89 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to rising prevalence of infectious diseases, growing burden of chronic diseases, increased adoption of molecular diagnostics, expansion of clinical laboratory infrastructure, government funding for diagnostic programs.
The next-generation in vitro diagnostics (ivd) market size is expected to see strong growth in the next few years. It will grow to $188.69 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine, expansion of genomic testing applications, growing adoption of point-of-care diagnostics, rising healthcare digitization, increasing investments in diagnostic R&D. Major trends in the forecast period include shift toward personalized and companion diagnostics, rapid adoption of point-of-care and decentralized testing, integration of multiplex and high-throughput assays, rising demand for early disease detection and screening, growth of non-invasive and liquid biopsy diagnostics.
The rising demand for personalized medicine is expected to drive the growth of the next-generation in vitro diagnostics (IVD) market moving forward. Precision medicine is a healthcare approach that tailors disease prevention and treatment based on an individual’s genetic profile, environment, and lifestyle. The growth of personalized medicine is fueled by the increasing availability of genomic data, enabling healthcare providers to develop targeted treatments based on a person’s unique genetic makeup, resulting in more effective care. Next-generation in vitro diagnostics (IVD) supports personalized medicine by delivering precise molecular and genetic insights that facilitate customized treatment and prevention strategies for individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the next-generation in vitro diagnostics (IVD) market.
Key players in the next-generation in vitro diagnostics (IVD) market are adopting strategic partnerships by collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, improve diagnostic accuracy, and broaden access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships involve companies leveraging each other’s strengths and resources to achieve shared benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to introduce Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative marks a significant advancement in prenatal care within the region, providing expectant parents with faster, more reliable, and cost-effective access to advanced genetic screening. The service employs Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, accommodating varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service throughout Colombia.
In February 2023, SD Biosensor Inc., a South Korea-based in-vitro diagnostics company, along with SJL Partners LLC, a South Korea-based investment firm, acquired Meridian Bioscience Inc. for $1.53 billion. Through this acquisition, SD Biosensor aims to leverage Meridian’s expertise in diagnostic products and raw materials used in immunological and molecular tests across various applications. Meridian Bioscience Inc. is a US-based diagnostic company specializing in in vitro diagnostic enzymes.
Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc.
North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation in vitro diagnostics (ivd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the next-generation in vitro diagnostics market by increasing costs associated with imported diagnostic instruments, consumables, and electronic components used in advanced testing platforms. These cost pressures have affected pricing and procurement cycles across molecular diagnostics and point-of-care testing segments, with Asia-Pacific and Europe being the most impacted regions due to their reliance on cross-border manufacturing and sourcing. However, tariffs have also encouraged localization of production, supply chain diversification, and domestic manufacturing investments, supporting long-term resilience and innovation within the market.
The next-generation in vitro diagnostics (ivd) market research report is one of a series of new reports that provides next-generation in vitro diagnostics (ivd) market statistics, including next-generation in vitro diagnostics (ivd) industry global market size, regional shares, competitors with a next-generation in vitro diagnostics (ivd) market share, detailed next-generation in vitro diagnostics (ivd) market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation in vitro diagnostics (ivd) industry. This next-generation in vitro diagnostics (ivd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation in vitro diagnostics (IVD) refers to advanced diagnostic tools and technologies that examine biological samples - such as blood, saliva, or tissue - outside the body to identify diseases, conditions, or infections with enhanced accuracy, speed, and personalization. These technologies often incorporate innovations like genomics, artificial intelligence, digital health platforms, and high-throughput sequencing. The main goal of next-generation IVD is to facilitate earlier, more precise, and patient-tailored diagnosis and monitoring of diseases, including cancer, infectious diseases, and genetic disorders.
The primary product categories in next-generation in vitro diagnostics (IVD) include consumables, instruments, software, and others. Core laboratory diagnostics involve centralized testing services that process a wide variety of biological samples using automated, high-throughput instruments and assays. This encompasses types such as core laboratory diagnostics, point-of-care testing, and molecular diagnostics. These tools are applied across various fields, including oncology, infectious diseases, diabetes, cardiology, and other diagnostic areas, serving a diverse range of end users like hospitals and clinics, diagnostic laboratories, academic and research institutions, and other healthcare providers.
The next-generation in vitro diagnostics (IVD) market consists of revenues earned by entities providing services such as genomic testing services, molecular diagnostics services, and companion diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation in vitro diagnostics (IVD) market also includes sales of molecular diagnostics kits, proteomics-based diagnostic kits, and NGS sample preparation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The next-generation in vitro diagnostics (ivd) market size is expected to see strong growth in the next few years. It will grow to $188.69 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine, expansion of genomic testing applications, growing adoption of point-of-care diagnostics, rising healthcare digitization, increasing investments in diagnostic R&D. Major trends in the forecast period include shift toward personalized and companion diagnostics, rapid adoption of point-of-care and decentralized testing, integration of multiplex and high-throughput assays, rising demand for early disease detection and screening, growth of non-invasive and liquid biopsy diagnostics.
The rising demand for personalized medicine is expected to drive the growth of the next-generation in vitro diagnostics (IVD) market moving forward. Precision medicine is a healthcare approach that tailors disease prevention and treatment based on an individual’s genetic profile, environment, and lifestyle. The growth of personalized medicine is fueled by the increasing availability of genomic data, enabling healthcare providers to develop targeted treatments based on a person’s unique genetic makeup, resulting in more effective care. Next-generation in vitro diagnostics (IVD) supports personalized medicine by delivering precise molecular and genetic insights that facilitate customized treatment and prevention strategies for individual patients. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and healthcare organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from six approvals in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the next-generation in vitro diagnostics (IVD) market.
Key players in the next-generation in vitro diagnostics (IVD) market are adopting strategic partnerships by collaborating with technology providers, research institutions, and healthcare organizations to accelerate innovation, improve diagnostic accuracy, and broaden access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships involve companies leveraging each other’s strengths and resources to achieve shared benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, partnered with Genetix, a Colombia-based human genetic diagnosis company, to introduce Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative marks a significant advancement in prenatal care within the region, providing expectant parents with faster, more reliable, and cost-effective access to advanced genetic screening. The service employs Yourgene Health’s IONA Nx NIPT Workflow, a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, accommodating varying sample volumes, and enables Genetix to offer a quality-assured prenatal screening service throughout Colombia.
In February 2023, SD Biosensor Inc., a South Korea-based in-vitro diagnostics company, along with SJL Partners LLC, a South Korea-based investment firm, acquired Meridian Bioscience Inc. for $1.53 billion. Through this acquisition, SD Biosensor aims to leverage Meridian’s expertise in diagnostic products and raw materials used in immunological and molecular tests across various applications. Meridian Bioscience Inc. is a US-based diagnostic company specializing in in vitro diagnostic enzymes.
Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc.
North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the next-generation in vitro diagnostics (ivd) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have moderately impacted the next-generation in vitro diagnostics market by increasing costs associated with imported diagnostic instruments, consumables, and electronic components used in advanced testing platforms. These cost pressures have affected pricing and procurement cycles across molecular diagnostics and point-of-care testing segments, with Asia-Pacific and Europe being the most impacted regions due to their reliance on cross-border manufacturing and sourcing. However, tariffs have also encouraged localization of production, supply chain diversification, and domestic manufacturing investments, supporting long-term resilience and innovation within the market.
The next-generation in vitro diagnostics (ivd) market research report is one of a series of new reports that provides next-generation in vitro diagnostics (ivd) market statistics, including next-generation in vitro diagnostics (ivd) industry global market size, regional shares, competitors with a next-generation in vitro diagnostics (ivd) market share, detailed next-generation in vitro diagnostics (ivd) market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation in vitro diagnostics (ivd) industry. This next-generation in vitro diagnostics (ivd) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Next-generation in vitro diagnostics (IVD) refers to advanced diagnostic tools and technologies that examine biological samples - such as blood, saliva, or tissue - outside the body to identify diseases, conditions, or infections with enhanced accuracy, speed, and personalization. These technologies often incorporate innovations like genomics, artificial intelligence, digital health platforms, and high-throughput sequencing. The main goal of next-generation IVD is to facilitate earlier, more precise, and patient-tailored diagnosis and monitoring of diseases, including cancer, infectious diseases, and genetic disorders.
The primary product categories in next-generation in vitro diagnostics (IVD) include consumables, instruments, software, and others. Core laboratory diagnostics involve centralized testing services that process a wide variety of biological samples using automated, high-throughput instruments and assays. This encompasses types such as core laboratory diagnostics, point-of-care testing, and molecular diagnostics. These tools are applied across various fields, including oncology, infectious diseases, diabetes, cardiology, and other diagnostic areas, serving a diverse range of end users like hospitals and clinics, diagnostic laboratories, academic and research institutions, and other healthcare providers.
The next-generation in vitro diagnostics (IVD) market consists of revenues earned by entities providing services such as genomic testing services, molecular diagnostics services, and companion diagnostics. The market value includes the value of related goods sold by the service provider or included within the service offering. The next-generation in vitro diagnostics (IVD) market also includes sales of molecular diagnostics kits, proteomics-based diagnostic kits, and NGS sample preparation kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Next-Generation in Vitro Diagnostics (IVD) Market Characteristics
3. Next-Generation in Vitro Diagnostics (IVD) Market Supply Chain Analysis
4. Global Next-Generation in Vitro Diagnostics (IVD) Market Trends and Strategies
5. Next-Generation in Vitro Diagnostics (IVD) Market Analysis of End Use Industries
7. Global Next-Generation in Vitro Diagnostics (IVD) Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Next-Generation in Vitro Diagnostics (IVD) Total Addressable Market (TAM) Analysis for the Market
9. Next-Generation in Vitro Diagnostics (IVD) Market Segmentation
10. Next-Generation in Vitro Diagnostics (IVD) Market Regional and Country Analysis
11. Asia-Pacific Next-Generation in Vitro Diagnostics (IVD) Market
12. China Next-Generation in Vitro Diagnostics (IVD) Market
13. India Next-Generation in Vitro Diagnostics (IVD) Market
14. Japan Next-Generation in Vitro Diagnostics (IVD) Market
15. Australia Next-Generation in Vitro Diagnostics (IVD) Market
16. Indonesia Next-Generation in Vitro Diagnostics (IVD) Market
17. South Korea Next-Generation in Vitro Diagnostics (IVD) Market
18. Taiwan Next-Generation in Vitro Diagnostics (IVD) Market
19. South East Asia Next-Generation in Vitro Diagnostics (IVD) Market
20. Western Europe Next-Generation in Vitro Diagnostics (IVD) Market
21. UK Next-Generation in Vitro Diagnostics (IVD) Market
22. Germany Next-Generation in Vitro Diagnostics (IVD) Market
23. France Next-Generation in Vitro Diagnostics (IVD) Market
24. Italy Next-Generation in Vitro Diagnostics (IVD) Market
25. Spain Next-Generation in Vitro Diagnostics (IVD) Market
26. Eastern Europe Next-Generation in Vitro Diagnostics (IVD) Market
27. Russia Next-Generation in Vitro Diagnostics (IVD) Market
28. North America Next-Generation in Vitro Diagnostics (IVD) Market
29. USA Next-Generation in Vitro Diagnostics (IVD) Market
30. Canada Next-Generation in Vitro Diagnostics (IVD) Market
31. South America Next-Generation in Vitro Diagnostics (IVD) Market
32. Brazil Next-Generation in Vitro Diagnostics (IVD) Market
33. Middle East Next-Generation in Vitro Diagnostics (IVD) Market
34. Africa Next-Generation in Vitro Diagnostics (IVD) Market
36. Next-Generation in Vitro Diagnostics (IVD) Market Competitive Landscape and Company Profiles
37. Next-Generation in Vitro Diagnostics (IVD) Market Other Major and Innovative Companies
40. Next-Generation in Vitro Diagnostics (IVD) Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Next-Generation In Vitro Diagnostics (IVD) Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses next-generation in vitro diagnostics (ivd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for next-generation in vitro diagnostics (ivd)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The next-generation in vitro diagnostics (ivd) market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Consumables; Instruments; Software2) By Diagnostic Modality: Core Laboratory Diagnostics; Point-Of-Care Testing; Molecular Diagnostics
3) By Application: Oncology Or Cancer; Infectious Diseases; Diabetes; Cardiology ; Other Applications
4) By End-User: Hospitals And Clinics; Diagnostic Laboratories; Academic And Research Institutions; Other End Users
Subsegments:
1) By Consumables: Assay Kits And Reagents; Specimen Bags and Tubes; Seals and Caps2) By Instruments: Automated Sample Preparation Systems; High-Throughput Molecular Diagnostic Analyzers; Next-Generation Sequencing Platforms; Integrated Diagnostic Workstations And Analysis Platforms; Digital PCR Systems And Advanced Real-Time PCR Instruments
3) By Software: Laboratory Information Management Systems; Specimen Tracking Software Modules; Cloud-Based Tracking Software
Companies Mentioned: F Hoffmann La Roche AG; Thermo Fisher Scientific Inc; Abbott Laboratories; Becton Dickinson And Company; Agilent Technologies Inc; Illumina Inc; Sysmex Corporation; Bio Rad Laboratories Inc; Revvity Inc; Exact Sciences Corporation; QIAGEN NV; DiaSorin SpA; Singular Genomics Systems Inc; Guardant Health Inc; Pacific Biosciences Of California Inc; Transasia Bio Medicals Ltd; J Mitra And Co Pvt Ltd; Roche Diagnostics International AG; Hologic Inc; Genetron Health Inc; Seegene Inc; BGI Genomics Co Ltd; Oxford Nanopore Technologies plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Next-Generation in Vitro Diagnostics (IVD) market report include:- F Hoffmann La Roche AG
- Thermo Fisher Scientific Inc
- Abbott Laboratories
- Becton Dickinson And Company
- Agilent Technologies Inc
- Illumina Inc
- Sysmex Corporation
- Bio Rad Laboratories Inc
- Revvity Inc
- Exact Sciences Corporation
- QIAGEN NV
- DiaSorin SpA
- Singular Genomics Systems Inc
- Guardant Health Inc
- Pacific Biosciences Of California Inc
- Transasia Bio Medicals Ltd
- J Mitra And Co Pvt Ltd
- Roche Diagnostics International AG
- Hologic Inc
- Genetron Health Inc
- Seegene Inc
- BGI Genomics Co Ltd
- Oxford Nanopore Technologies plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 129.89 Billion |
| Forecasted Market Value ( USD | $ 188.69 Billion |
| Compound Annual Growth Rate | 9.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 24 |
